FDA early alert: Arrow International removes catheters and guidewires with hydrophilic-coated spring wire guides over coating detachment and embolism risk
Published November 15, 2026 · Coverage November 8–14, 2026, Pacific · High priority
The Food and Drug Administration (FDA) posted an early alert on November 10, 2026 about Arrow International, a subsidiary of Teleflex Incorporated, which has told customers to remove certain products that contain Spring Wire Guide components. Arrow sent the letter on November 5, 2026, telling customers to check inventory, stop using and distributing affected product, quarantine it and return it. Teleflex confirmed that the hydrophilic coating may swell unevenly when hydrated with saline, clump and potentially detach. Detached coating could release particles into the bloodstream and raise the risk of emboli. As of November 5, 2026, the firm had reported no serious injuries or deaths.

Background
An FDA early alert notifies the public of a potentially high-risk device issue while FDA reviews it. The affected Arrow coated guidewires help place catheters in blood vessels, and the recall also covers pressure-injectable catheters containing these guidewires that are used to deliver medicines and fluids and collect blood samples.
Who this affects
Hospitals and other facilities that stock or use Arrow hydrophilic-coated marked guidewires and Arrow pressure-injectable catheters and kits that contain them (vascular access teams, interventional radiology, critical care, supply chain)
Why it matters
Arrow recommends that affected guidewires and catheter kits be removed from where they are used or sold. Inference: removing them can interrupt vascular access supply until substitutes are in place. Inference: facilities that placed lines with affected products before the alert may want clinical review of any unexplained embolic events.
Recommended action
- Search inventory and procedure carts against the full FDA affected-product list and quarantine matches
- Return affected product to Teleflex/Arrow International and pass the notice to any facility you supplied
- Arrange substitute guidewires and catheter kits with supply chain and the vascular access team
- Report adverse events or quality problems to MedWatch
Implementation playbook
- Immediately retrieve the full affected-product list linked from the FDA early alert, search storerooms, procedure carts and kits for matches, stop using and distributing any match, and quarantine it. The Arrow letter, as FDA reports it, says to check inventory, cease use and distribution, and quarantine immediately. Owner: Supply chain with the Vascular access team. Due: immediately.
- Return the quarantined product to Arrow International and pass the notice to any facility the hospital supplies. Owner: Supply chain. Due: 2026-11-21.
- Confirm substitute guidewires and pressure-injectable catheter kits for vascular access, interventional radiology and critical care. Owner: Supply chain and Clinical engineering. Due: 2026-11-18.
- Ask clinical leaders whether unexplained embolic events after lines placed with affected product warrant review, and report any adverse event to MedWatch. Owner: Risk management. Due: 2026-12-15.
Scope and timing
- Authority status
- Other (FDA early alert)
- Responsible owner
- Supply chain, Clinical engineering, Vascular access and Interventional radiology, Risk management
- Publication date
- 2026-11-10
- Other dates
- 2026-11-05 Arrow International letter to affected customers; injury status as of 2026-11-05
Not established
The full list of affected product codes and lots linked from the FDA page was not retrieved.
Sources
Complete edition and supplemental material
This article in the complete report →
Executive triage, source-coverage limitations, context and forward horizons remain in the complete report.
Read the entire Compliance Sweep report →